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บทคดัยอ่ 
วตัถปุระสงค์: เพื่อศกึษาความชุกของเชือ้แบคทเีรยีที่เป็นสาเหตุ ความไวต่อยาต้าน
จุลชีพ ยาต้านจุลชีพที่เป็นทางเลือกรักษา  และผลลัพธ์ทางคลินิก รวมถึงปัจจัยที่
สมัพนัธก์บัความลม้เหลวทางการรกัษาในผูป่้วยโรคปอดอกัเสบในโรงพยาบาล (HAP) 
และปอดอกัเสบที่เกี่ยวข้องกับเครื่องช่วยหายใจ (VAP) วิธีการศึกษา: การศึกษา
ย้อนหลงัครัง้นี้รวบรวมผูป่้วยโรคปอดอกัเสบที่รกัษาตวัในโรงพยาบาลหวัหนิ ซึ่งเป็น
โรงพยาบาลทัว่ไป ระหว่างเดอืนมกราคม - ธนัวาคม พ.ศ. 2556 เกณฑค์ดัเลอืกผูป่้วย 
คอื อายุมากกว่า 18 ปีขึน้ไป และผูป่้วยโรคปอดอกัเสบที่ตรงตามนิยามของ HAP และ 
VAP ทัง้นี้ ระบุเชือ้ที่เป็นสาเหตุจากเชือ้ที่เพาะได้จากผูป่้วยปอดอกัเสบ ผลลพัธ์ทาง
คลินิกได้แก่ อัตราความล้มเหลวทางการรักษาและอัตราตายภายใน 30 วนั ผล
การศึกษา: มผีูป่้วยร่วมการศกึษา 106 ราย เป็นเพศชายรอ้ยละ 56.6% มคี่ามธัยฐาน
ของอายุเท่ากบั 72 ปี (พสิยั 18 - 95 ปี) ผูป่้วยรอ้ยละ 81.1 มโีรคร่วม และรอ้ยละ 27.4 
เป็นผูป่้วยในหออภบิาล (ไอซยี)ู ในผูป่้วย 91 รายที่เพาะแลว้พบเชือ้ พบเชือ้แบคทเีรยี
จ านวน 155 สายพนัธุ์ในสิง่ส่งตรวจเสมหะ โดยเป็นผูป่้วย HAP 46 ราย และ VAP 60 
ราย โดยใน HAP เชื้อแบคทีเรีย 3 ล าดับแรก คือ A. baumannii (ร้อยละ 23.8), P. 
aeruginosa (ร้อยละ 20.6) และ K. pneumoniae (ร้อยละ 17.5) และใน VAP พบ เชื้อ
แบคทีเรีย 3 ล าดับแรก คือ A. baumannii (ร้อยละ  32.6), P. aeruginosa (ร้อยละ 
18.5) และ  S. aureus (ร้อยละ 22.8) พบว่ายา  imipenem และ  meropenem เ ป็น
ทางเลือกรักษาที่ดีส าหรับเชื้อ K. pneumoniae ในขณะที่ยา vancomycin เป็นยาที่
ครอบคลุมเชือ้ methicillin-resistant S. aureus ที่ด ีจากผูป่้วย 106 ราย พบอตัราตาย
และความลม้เหลวทางการรกัษารอ้ยละ 17.9 และ 34 ตามล าดบั โดยการใชย้าต้านจุล
ชีพอย่างเหมาะสมและการติดเชื้อ multi-drug resistant A. baumannii เป็นปัจจัยที่
สมัพนัธ์กบัความล้มเหลวทางการรกัษา (ค่า odds ratios เท่ากบั 0.126 และ 3.624, 
ตามล าดบั) สรุป: การศกึษาครัง้นี้มคีวามชกุของเชือ้แบคทเีรยีทีเ่ป็นสาเหตุคล้ายคลงึ
กบัโรงพยาบาลขนาดใหญ่ ส่วนการใช้ยาต้านจุลชพีอย่างเหมาะสมและการติดเชื้อ 
MDR-A. baumannii สมัพนัธก์บัผลลพัธท์างการรกัษาทีไ่ม่พงึประสงค ์ 
ค าส าคญั: เชือ้จุลชพีทีเ่ป็นสาเหตุ, ผลลพัธ์ทางคลนิิก, โรคปอดอกัเสบ 
 
 
Abstract 
Objectives: To assess the prevalence of etiologic bacteria of hospital-acquired 
pneumonia (HAP) and ventilator-associated pneumonia (VAP), the antibiotic 
susceptibility of the isolated pathogens and the prescribed antimicrobial therapy. 
Relationship between select factors and clinical outcomes was tested. Methods: 
This retrospective study included HAP or VAP patients admitted to Hua-hin 
Hospital, a general hospital, from January to December 2013. Patients aged 18 
or older and diagnosed with HAP or VAP were included. The bacteria isolated 
from HAP or VAP patients were listed as etiologic pathogens and the clinical 
outcomes were classified as treatment failure and 30-day mortality rate. Results: 
Of the 106 patients recruited, their median age was 72 years (range: 18 - 95 
years). It was found that 56.6% of 106 patients were male, 81.1% had comorbid 
diseases and 27.4% were admitted to the intensive care unit. With 15 patients 
with negative sputum culture, 91 patients contributed 155 isolated organisms. Of 
the 46 HAP cases, A. baumannii (23.8%), P. aeruginosa (20.6%) and K. 
pneumoniae (17.5%) were the most frequently found isolated organisms; while 
A. baumannii (32.6%), P. aeruginosa (18.5%) and S. aureus (22.8%) were the 
most frequently identified among 60 VAP cases. Imipenem and meropenem were 
a good option for K. pneumoniae; while vancomycin remained the best drug 
against methicillin-resistant S. aureus. Of the 106 cases, the crude 30-day 
mortality rate and treatment failure were 17.9% and 34%, respectively. The 
appropriate antimicrobial treatment and multi-drug resistant A. baumannii were 
the two factors significantly associated with treatment failure in the opposite 
directions, with odds ratios of 0.126 and 3.624, respectively. Conclusion: Our 
findings illustrated the pattern of causative pathogens in a general hospital that 
seemed to have the same trouble as in a larger-sized hospital. The appropriate 
antimicrobial treatment and multi-drug resistant A. baumannii were related to the 
unfavorable outcome.  
Keywords: causative pathogens, clinical outcome, pneumonia  
 
Introduction
Pneumonia, especially nosocomial infection (NI), is a 
major public health problem and a leading cause of hospital 
mortality in Thailand. Danchaivijitr et al. performed a cross- 
sectional study among 42 hospitals nationwide in March 2001. 
They found that lower respiratory tract was the first-ranked 
source of infection (34.1%).1 A subsequent study by the same 
author in 2006 found that lower respiratory tract infection 
remained the nosocomial infection with the highest prevalent.2 
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Moreover, patients with pneumonia during a hospital stay, 
either hospital-acquired pneumonia (HAP) or ventilator-
associated pneumonia (VAP), had poorer clinical outcomes. 
Limpawattana et al. performed a health situation analysis of 
hospitalized Thai older persons in 2010 and found that 
mortality rates were highest in the elders with pneumonia.3 
According to the frequent unfavorable outcomes, there has 
been an increasing need to optimize antibiotic utilization to 
treat most common causative pathogens. Many previous 
studies indicated that the inappropriate treatment, either a use 
of antibiotics with no pathogen coverage or a delay to start 
antibiotics within 24 hours of sepsis, caused a higher mortality 
rate and a longer period of hospitalization.4-6 In this drug 
resistance era, it has been highly difficult to optimize the 
antimicrobial selection for causative pathogens, particularly 
those multidrug-resistant Acinetobacter baumannii and 
Pseudomonas aeruginosa, extended spectrum beta-
lactamases (ESBL)-producing Klebsiella pneumoniae and 
methicillin-resistant Staphylococcus aureus. This frustrating 
situation was supported by the work of Luna et al. which 
showed that the coverage rates of empirical therapy in 
patients with VAP caused by Acinetobacter species, Klebsiella 
pneumoniae, P. aeruginosa and S. aureus were only 15.6%, 
23.5%, 46.2% and 21.9%, respectively.7  
The proportions of various etiologic microorganisms 
differed among levels of hospitals. However, the studies on 
pathogenic microorganism prevalence have been done mostly 
in tertiary health care settings especially medical school 
hospitals. The types of pathogens and their antimicrobial 
susceptibility in community and general hospitals could 
however have been different from the ones of medical 
schools. It was found that A. baumannii was the most common 
isolated pathogen in the three university hospitals8-10, whereas 
Klebsiella spp. was the most frequently isolated organism from 
nosocomial pneumonia patients in a general hospital on the 
Eastern Thailand.11  
In Hua-hin Hospital, a general hospital in Prachuap Khiri 
Khan province, the problem of antimicrobial resistance has 
been increasing. Recently, the study in our institution by 
Santimaleeworagun and colleagues found that the appropriate 
antimicrobial therapy defined as receiving at least one 
antimicrobial agent within 24 hours was associated with a 
significant lower 30-day mortality rate.12 Other factors specific 
to this general hospital, however, have not been known. 
Therefore, the objective of this present study was to 
determine the prevalence of causative pathogens of HAP and 
VAP and the antimicrobial susceptibility of the most common 
isolated organisms. Select factors were also tested for the 
association with the clinical outcomes in HAP and VAP 
patients.  
 
Materials and Methods 
 
This retrospective review study gathered the patients’ data 
from an electronic medical records database. We included the 
patients with HAP or VAP between January and December 
2013, admitted to Hua-hin Hospital, a 400-bed general 
hospital in Prachuap Khiri Khan province, Thailand. The 
protocol was approved by the research ethics committee of 
our institute with a waiver for informed consent [No. 18/2557; 
issued on December 19th, 2014].  
 
Definitions    
Pneumonia, based on the American Thoracic Society 
criteria, was diagnosed by a set of clinical features. These 
criteria included 1) having at least 2 of 4 signs of the systemic 
inflammatory syndrome (SIRS) (body temperature of > 38 ºC 
or < 36 ºC, respiratory rate of > 20 beats per minute, heart 
rate of > 90 beats per minute, leukocytosis defined as white 
blood cells (WBC) of > 12,000 cells per millilitre, or leukopenia 
defined as WBC of < 4,000 cells per millilitre), and 2) clinical 
symptoms consisting of cough, purulent sputum or pleuritic 
chest pain. In addition, patients had to be confirmed by lung 
imaging, usually with a new or persistent infiltrate seen on 
chest radiography.  
Hospital-acquired pneumonia (HAP) was defined as a 
pneumonia in the patient admitted to the hospital for more 
than 48 hours. Ventilator-associated pneumonia (VAP), a 
subset of HAP, was defined as patients diagnosed with 
pneumonia after being on a mechanical ventilator for more 
than 48 hours.13 Multi-drug resistant (MDR) pathogen was 
defined as an isolated microorganism resistant to greater than 
3 classes of antimicrobials. The appropriate antimicrobial 
therapy in this study was defined as receiving antimicrobials 
that could cover the causative pathogen within 24 hours after 
the diagnosis of the suspected pneumonia. Septic shock was 
referred to the non-responsiveness to the fluid loading in 
patients with hypotension (i.e., mean arterial blood pressure 
of < 65 mmHg) and one or more vasopressor was indicated 
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to normalize blood circulation. Shocks of other origins, i.e., 
hypovolemic, cardiogenic shock, and obstructive, were ruled 
out. Impaired renal function was defined as a serum creatinine 
elevation of more than 50% of the baseline level. Steroid use 
was defined as a use of a prednisolone dose of > 10 mg daily 
for more than 2 weeks.  
In terms of clinical outcomes, treatment failure included a 
failure and death. Patients with failure were those whose 
clinical symptoms got worse or their antimicrobial agent 
against causative pathogens had to be changed or added. 
Death was the patient who died within 30 days of HAP or VAP 
acquisition.  
 
Participants  
The inclusion criteria in this study consisted of 1) age of 
18 years or older 2) being diagnosed with pneumonia, and 3) 
being compatible with the definition of HAP or VAP. Those 
patients transferred to the other hospital and whose follow-up 
information could not be obtained were excluded from the 
study. Patients with incomplete medical record data were also 
excluded.  
 
Data collection  
The medical records and the report of antimicrobial 
susceptibility were retrieved from the computer database for 
clinical information. Such information consisted of age, sex, 
underlying diseases, ward type, mechanical ventilator use, 
septic shock status, hepatic function, renal function, 
immunocompromised status, antimicrobial regimen (dosage 
and duration), antimicrobial susceptibility, length of hospital 
stay, source of infection, vital sign and clinical outcomes.  
The identification of pathogens from the good quality 
sputum (i.e., WBC of > 25 cells and epithelial cell of < 10 cells) 
was verified by morphology, Gram stain, standard 
biochemistry tests, coagulase test, and selective media for 
culturing, if available. Susceptibility testing was based on the 
antimicrobial susceptibility testing (AST) performed routinely 
with the disk diffusion method, also called Kirby-Bauer 
method. This method provided qualitative results reported as 
susceptible (S), intermediate (I) or resistant (R), based on the 
interpretation of clinical and laboratory standards.14  
 
Statistical analysis 
The descriptive statistics were used to depict 
characteristics of the participants, antibiotic regimens, 
antimicrobial susceptibility results and clinical outcomes (i.e., 
mortality rate and treatment failure), among patients with HAP 
or VAP. Chi-square or Fisher's exact test, as appropriate, was 
used to determine the correlation between the categorical 
factors and clinical outcomes. For continuous data, Student t-
test or Mann-Witney U test, as appropriate, was used to 
compare the mean or median, respectively, between the two-
group clinical outcomes. All significant variables in the 
univariate analysis at a P-value of < 0.1 were further tested 
by the logistic regression analysis. The dependent variable 
was treatment failure, whereas the outcome-related 
independent variables previously described included age15,16, 
underlying disease15, type of pathogen17,18, multiple-bacterial 
infection17, steroid use16, renal function impairment16, septic 
shock9,15, bacteremia19 and the appropriate antimicrobial 
treatment.19 Data analysis was conducted by using PSPP 
version 0.8.5, an open-source statistical software, available at 
https://www.gnu.org/software/pspp/. Statistical significance 
level for all tests was set at a type I error of 5%.  
 
Results 
 
During the study period, 106 participants with HAP (n = 
46) or VAP (n = 60) were recruited. Of these 106 patients, 
slightly more than half were male (56.6%). Their median age 
was 72 years with a range of 18 - 95 years. Eighty-six patients 
(81.1%) had co-morbid diseases and 29 patients (27.4%) 
were admitted to the intensive care unit. The median time prior 
to HAP or VAP acquisition was 8 days with a range of 2 - 157 
days (Table 1).  
 
Causative pathogens and their antimicrobial 
susceptibility  
According to the negative sputum culture in 15 cases 
(14.2%), the isolated organisms in 91 patients with HAP or 
VAP were obtained (Table 2). Of these 91 cases, mono- and 
poly-microbial isolations were found in 35 cases (38.5%) and 
56 cases (61.5%), respectively, resulting in 155 isolated 
organisms. Among these 155 isolates, the majority were Gram 
negative bacteria (81.3%). The top-three pathogens included 
A. baumannii, P. aeruginosa and S. aureus. For HAP cases, 
the most frequently found isolated pathogens were A. 
baumannii followed by P. aeruginosa and K. Pneumonia; while 
A. baumannii, P. aeruginosa and S. aureus were the top-three 
isolated organisms among VAP cases.  
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 Table 1   Characteristics of patients with hospital-acquired 
pneumonia or ventilator-associated pneumonia (N = 106).   
Characteristics N (%) 
Gender: male  60 (56.9) 
Age, years, median (range) 72 (18 - 95) 
Being treated in the intensive care unit 29 (27.4) 
Duration before HAP or VAP diagnosis (days), median 
(range)  
8 (2 - 157) 
Length of hospitalization after HAP or VAP diagnosis (days), 
median (range)  
12 (1 - 57) 
Underlying diseases*  86 (81.1) 
   Hypertension 
   Diabetes mellitus 
   Cerebrovascular disease 
   Dyslipidemia 
   Heart failure 
   Anemia 
   Chronic obstructive pulmonary disease 
41 (30.5) 
21 (15.7) 
16 (11.9) 
15 (11.2) 
14 (10.5) 
14 (10.5) 
13 (9.7) 
Mechanical ventilator use 54 (51.9) 
  * For a given patient, more than one disease could be found.  
 
 
     
 Table 2  The causative pathogens (N = 155 isolates) in 
patients with hospital-acquired pneumonia (HAP) or ventilator-
associated pneumonia (VAP). 
 
Number of isolates (%) 
HAP  
(n = 63 isolates)  
VAP  
(n = 92 isolates) 
A. baumannii 15 (23.8) 30 (32.6) 
   Multi-drug resistant strains 15 27 
P. aeruginosa 13 (20.6) 17 (18.5) 
   Multi-drug resistant strains 1 2 
K. pneumonia 11 (17.5) 14 (15.2) 
   Third generation cephalosporin  
   non-susceptible strains 
4 0 
S. aureus 7 (11.1) 21 (22.8) 
   Methicillin resistant S. Aureus  19 
E. coli   8 (12.7) 2 (2.2) 
Enterobacter spp. 4 (6.4) 6 (6.5) 
Proteus spp. 1 (1.6) 2 (2.2) 
Streptococcus spp. 1 (1.6) 0 
Other Gram negative bacilli 3 (4.7) 0 
Total 63 (100) 92 (100) 
 
 
Table 3 shows the antimicrobial susceptibility of the most 
common isolated organisms. Colistin was still the most active 
agent against P. aeruginosa whereas the carbapenems such 
as imipenem and meropenem were an effective choice for K. 
pneumoniae.  Vancomycin remained an effective antibiotic to 
cover S. aureus while fosfomycin was no longer an option.  
 
 
 
 
 Table 3  The antimicrobial susceptibility of A.baumannii, P. 
aeruginosa, K. pneumoniae and S. aureus.  
Antimicrobials 
Number of isolates (%) 
A. baumannii 
(n = 45) 
P. aeruginosa 
 (n = 30) 
K. pneumoniae 
(n = 25) 
S. aureus 
(n = 28) 
Amikacin 4 (6.7) 27 (90) 22 (88) - 
Gentamicin 3 (6.7) 27 (90) 18 (72) 4 (14.3) 
Ceftazidime 2 (4.4) 24 (80) 12 (48) - 
Ceftriaxone - - 13 (52) - 
Ciprofloxacin 2 (4.4) 27 (90) - - 
Cefoperazone/ 
Sulbactam 
2 (4.4) 20 (67) - - 
Imipenem 2 (4.4) 22 (73.3) 25 (100) - 
Meropenem 2 (4.4) 22 (73.3) 25 (100) - 
Ertapenem - - 24 (100) - 
Colistin - 30 (100) - - 
Cefoxitin - - - 4 (14.3) 
Clinadamycin - - - 4 (14.3) 
Fosfomycin - - - 4 (14.3) 
Vancomycin    28 (100) 
 
Clinical outcomes  
Regarding the clinical outcomes among 106 pneumonia 
cases, rates of crude 30-day mortality and treatment failure 
were 17.9% and 34%, respectively. According to the type of 
pneumonia, patients with HAP (n = 46) vs. VAP (n = 60) had 
comparable crude 30-day mortality rates of 13.0% and 15.0%, 
respectively. However, treatment failure rate of those with 
HAP (23.9%) was slightly higher than that among VAP 
patients (16.7%). Of all the 91 patients with positive bacterial 
culture, only 65 patients (71.4%) received appropriate 
antimicrobial treatment covering the causative pathogens.  
 
Predictive factors of clinical outcomes  
All variables as factors potentially related to the treatment 
failure were analyzed in the univariate analysis. These 
variables included age, underlying disease, type of pathogens, 
multiple-bacterial infection, steroid use, renal function 
impairment, septic shock, bacteremia and the appropriate 
antimicrobial treatment. The results from univariate analyses 
showed that the only two factors significantly associated with 
treatment failure were MDR-A. baumannii infection and the 
appropriate antimicrobial treatment. In the following logistic 
regression analysis, the appropriate antimicrobial treatment 
and MDR-A. baumannii infection remained the factors 
significantly related to the treatment failure with the adjusted 
ORs of 0.126 (95% CI: 0.043 - 0.365) and 3.624 (95% CI: 
1.269 - 10.345), respectively.  
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Discussions and Conclusion 
 
Among 106 cases of pneumonia, we found more VAP (60) 
than HAP (46) cases. Of these 106 cases, sputum cultures 
were successfully obtained in 91 patients resulting in 155 
isolated organisms. The first two most found organisms were 
A. baumannii and P. aeruginosa both in VAP and HAP cases; 
while K. pneumoniae and S. aureus were the third most 
identified organisms for VAP and HAP cases, respectively. 
Imipenem and meropenem were the good choice for K. 
pneumoniae; while vancomycin remained a good drug to 
cover MRSA. Among all 106 pneumonia cases, the crude 30-
day mortality rate was 17.9% while the treatment failure rate 
was 34.0%. While the appropriate antimicrobial treatment was 
a significant protective factor of the treatment failure, multi-
drug resistant A. baumannii was a significant aggravating one. 
Etiologic pathogens for HAP and VAP are Gram negative 
bacilli, specifically P. aeruginosa and A. baumannii and Gram 
positive cocci, especially K. pneumoniae and S. aureus. As 
expected, we also found causative bacteria similar to those in 
several reports in Thailand. Reechaipichitkul et al. studied the 
causative agents among HAP and VAP patients at a tertiary 
care teaching hospital in the north-east of Thailand from 2008 
to 2009. They found that nearly 70% of HAP cases were 
caused by P. aeruginosa, A. baumannii, and K. pneumoniae; 
and about 70% of VAP were caused by A. baumannii, P. 
aeruginosa, and K. pneumoniae.10 These pathogens were also 
found in a study by Weerarak et al. in a medical school 
hospital in the central part of Thailand. They found that A. 
baumannii was the most common organism followed by K. 
pneumoniae, P. aeruginosa and MRSA.9 Another study by 
Luksamijarulkul and co-workers on the etiology of nosocomial 
pneumonia at a provincial hospital revealed that Klebsiella 
spp. was the number-one cause.11 At present, previous 
studies and our present study revealed that bacterial 
pathogens of nosocomial pneumonia were common among 
different levels of healthcare settings. However, a 
considerable discrepancy in the prevalence of individual 
pathogenic bacteria among various levels of healthcare 
institutes was of concern. For any given institutes, this 
discrepancy emphasizes the importance of the tailor-made 
antimicrobial selection approach. Continuous local studies on 
the microbial sensitivity should be encouraged.  
The appropriate regimen for empirical therapy was 
evaluated from the antimicrobial agents covering the most 
causative bacteria. However, there were no susceptibility 
results of colistin against K. pneumoniae and A. baumannii 
because of the absent breakpoint for disk diffusion based on 
clinical laboratory standard in 2014. Fortunately, the colistin-
resistant Gram negative bacteria were scant in Thailand.10,20; 
hence, colistin remained the therapeutic choice for 
Enterobacteriaceae and A. baumannii.  
As a medium-sized general hospital, mortality rate in our 
study (17.9%) was much lower than that in a medical teaching 
hospital (45.9%) as reported by Weerarak and colleagues.9 
This discrepancy could be attributable to the fact that a large 
proportion of patients in Weerarak et al. study were severely 
ill (42.5%) which led them to a rapid mortality. Another 
possible reason was that a larger proportion of patients in our 
study (71.4%) received appropriate antimicrobial therapy while 
only 58.9% in the work of Weerarak and colleagues did. 
In this study, we found the appropriate therapy a 
significant protective factor for the treatment failure. This 
predictor was also reported in a few previous studies.21-23 
Importantly, another factor such as HAP or VAP caused by A. 
baumannii was significantly correlated with a poor clinical 
outcome. Tseng and colleagues suggested that the patients 
with A. baumannii VAP had a higher mortality than with other 
organisms.18 
There were certain limitations in our study conduct and 
hence cautions with our findings. With various sensitivity of 
resistant bacteria, appropriate antimicrobials in each hospital 
were different. In our study, APACHE II score, predictor 
associated with mortality patient with pneumonia19, was not 
calculated; hence, biased results could be expected. However, 
the patient characteristic information such as age, renal 
function, and shock, which were important parameters in 
APACHE II score, had been already included in the univariate 
analysis.  
This study has illustrated the pattern of causative 
pathogens for VAP and HAP in a general hospital comparable 
to that in a larger-sized hospital. Additionally, the appropriate 
antimicrobial treatment was associated with a better treatment 
outcome. In the resistant organism era, the individualized 
antibiotic regimen is a strategy to improve the quality of 
pneumonia treatment.  
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